In December 2015, an open-label, randomized Phase 3 trial (NCT02631876) were conducted to investigate the safety and efficacy of IMGN853 along with the selected single-agent chemotherapy in the treatment of women with platinum-resistant FRα positive advanced epithelial ovarian cancer, primary peritoneal cancer and/or fallopian tube cancer.239 It is the first FRα-targeting ADC candidate to enter into human clinical trials. This evidence concerns the gene FOLR1 and peritoneum cancer.